Optic Neuritis (Ophthalmology) – Drugs In Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Optic Neuritis – Drugs In Development, 2021, provides an overview of the Optic Neuritis (Ophthalmology) pipeline landscape.Optic neuritis is an inflammation of the optic nerve, the bundle of nerve fibers that transmits visual information from eye to brain. Symptoms include pain, vision loss, dyschromatopsia, Uhthoff’s phenomenon and flashing lights. Risk factors include age and genetic mutations.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Optic Neuritis – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Optic Neuritis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Optic Neuritis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Optic Neuritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 1, 3 and 5 respectively. Similarly, the Universities portfolio in Phase II and Discovery stages comprises 1 and 1 molecules, respectively.

Optic Neuritis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Optic Neuritis (Ophthalmology).

– The pipeline guide reviews pipeline therapeutics for Optic Neuritis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Optic Neuritis (Ophthalmology) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Optic Neuritis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Optic Neuritis (Ophthalmology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Optic Neuritis (Ophthalmology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Optic Neuritis (Ophthalmology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

Accure Therapeutics SL

EnhanX Biopharm Inc

Japan Innovative Therapeutics Inc

Meta-IQ ApS

Mitochon Pharmaceuticals Inc

Noveome Biotherapeutics Inc

ReNetX Bio

SanBio Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Optic Neuritis - Overview

Optic Neuritis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Optic Neuritis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Optic Neuritis - Companies Involved in Therapeutics Development

Accure Therapeutics SL

EnhanX Biopharm Inc

Japan Innovative Therapeutics Inc

Meta-IQ ApS

Mitochon Pharmaceuticals Inc

Noveome Biotherapeutics Inc

ReNetX Bio

SanBio Co Ltd

Optic Neuritis - Drug Profiles

ACT-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AXER-204 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ENX-201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

etomoxir - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapies for Glaucoma, Optic Neuritis and Retinitis Pigmentosa - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

gypenoside - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MP-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MP-201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Optic Neuritis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ST-266 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Optic Neuritis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Optic Neuritis - Dormant Projects

Optic Neuritis - Discontinued Products

Optic Neuritis - Product Development Milestones

Featured News & Press Releases

Oct 21, 2020: Noveome Biotherapeutics announces publication of preclinical results demonstrating the neuroprotective properties of amnion-derived multipotent pCells in spinal cord and retinal ganglion cells

May 15, 2019: Bionure appoints Dr. Lucia Septien as chief medical officer

May 09, 2019: Noveome Biotherapeutics announces publication of further preclinical results supporting the neuroprotective properties of ST266 in retinal ganglion cells

May 07, 2019: Neuroprotection Biotech Bionure Reports Successful Phase 1 Study for Lead Candidate BN201

Oct 09, 2018: Bionure appoints Dr. Laurent Nguyen as CEO

May 16, 2018: Bionure initiates a Phase 1 clinical trial of its lead compound BN201 in the United Kingdom

Jan 31, 2017: Noveome Biotherapeutics Publishes Data Demonstrating Anti-inflammatory Activity of ST266 in a Preclinical Model of Optic Neuritis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Optic Neuritis, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Optic Neuritis – Pipeline by Accure Therapeutics SL, 2021

Optic Neuritis – Pipeline by EnhanX Biopharm Inc, 2021

Optic Neuritis – Pipeline by Japan Innovative Therapeutics Inc, 2021

Optic Neuritis – Pipeline by Meta-IQ ApS, 2021

Optic Neuritis – Pipeline by Mitochon Pharmaceuticals Inc, 2021

Optic Neuritis – Pipeline by Noveome Biotherapeutics Inc, 2021

Optic Neuritis – Pipeline by ReNetX Bio, 2021

Optic Neuritis – Pipeline by SanBio Co Ltd, 2021

Optic Neuritis – Dormant Projects, 2021

Optic Neuritis – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Optic Neuritis, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Mechanism of Actions, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports